Dystonia: Genetics and treatment update

Neurologist

Volumn 12, Issue 2, 2006, Pages 74-85

  Bhidayasiri, Roongroj ^a,b  

^a UCLA MEDICAL CENTER   (United States)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Botulinum toxin; Deep brain stimulation; Dopa responsive dystonia; Dystonia; Oppenheim's dystonia

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; BENZATROPINE MESILATE; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CARBAMAZEPINE; CARBIDOPA; CARISOPRODOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; CYCLOBENZAPRINE; DOPAMINE RECEPTOR BLOCKING AGENT; LEVODOPA; METAXALONE; MUSCARINIC AGENT; MUSCLE RELAXANT AGENT; PILOCARPINE; PIMOZIDE; PYRIDOSTIGMINE; RESERPINE; RILUZOLE; RISPERIDONE; TETRABENAZINE; TIZANIDINE; TRIHEXYPHENIDYL;

AUTOSOMAL DOMINANT DISORDER; BLEPHAROSPASM; BLURRED VISION; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DISEASE CLASSIFICATION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; GENE EXPRESSION; GENE LOCUS; GENETIC ANALYSIS; GENETIC PROCEDURES; HALLUCINATION; HEREDITARY ESSENTIAL MYOCLONUS; HUMAN; LONG TERM CARE; NEUROLOGIC DISEASE; NEUROSURGERY; PALLIDOTOMY; PARKINSONISM; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; SEDATION; SEGAWA DISEASE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TARDIVE DYSKINESIA; TORSION DYSTONIA; URINE RETENTION;

BACLOFEN; BOTULINUM TOXINS; CHOLINERGIC ANTAGONISTS; DYSTONIA; DYSTONIA MUSCULORUM DEFORMANS; GABA AGONISTS; HUMANS;

EID: 33645100655     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000195831.46000.2d     Document Type: Review

References (131)

1. Oppenheim H. Uber eine eigenartige Krampfkrankheit des kindlichen und jugendlichen Alters (dysbasia lordotica progressiva, dystonia musculorum deformans). Neurol Centrabl. 1911;30:1090-1107.
2. Flatau E, Sterling W. Progressiver Torsionspasms bie Kindern. Z Gesamte Neurol Psychiatr. 1911;7:586-612.
3. Fahn S. Concept and classification of dystonia. Adv Neurol. 1988;50:1-8.
4. Marsden CD, Harrison MJG. Idiopathic torsion dystonia. Brain. 1974;97:793-810.
5. Bressman SB, de Leon D, Brin MF. Idiopathic torsion dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol. 1989;26:612-620.
6. Greene P, Kang UJ, Fahn S. Spread of symptoms in idiopathic torsion dystonia. Mov Disord. 1995;10:143-152.
7. Hartmann A, Pogarell O, Oertel WH. Secondary dystonias. J Neurol. 1998;245:511-518.
8. Bressman SB. Dystonia genotypes, phenotypes, and classification. Adv Neurol. 2004;94:101-107.
9. Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv Neurol. 1998;78:1-10.
10. Bressman SB, de Leon D, Kramer PL, et al. Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation. Ann Neurol. 1994;36:771-777.
11. Opal P, Tintner R, Jankovic J, et al. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord. 2002;17:339-345.
12. Marsden CD. Investigation of dystonia. Adv Neurol. 1988;50:35-44.
13. Grundmann K, Laubis-Herrmann U, Bauer I, et al. Frequency and phenotypic variability of the GAG deletion of the DYT1 gene in an unselected group of patients with dystonia. Arch Neurol. 2003;60:1266-1270.
14. Eldridge R. The torsion dystonias: literature review and genetic and clinical studies. Neurology. 1970;20:1-78.
15. Pauls DL, Korczyn AD. Complex segregation analysis of dystonia pedigrees suggests autosomal dominant inheritance. Neurology. 1990; 40:1107-1110.
16. Zilber N, Korczyn AD, Kahana E, et al. Inheritance of idiopathic torsion dystonia among Jews. J Med Genet. 1984;21:13-20.
17. Risch NJ, Bressman SB, deLeon D, et al. Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. Am J Hum Genet. 1990;46:533-538.
18. Saunders-Pullman R, Shriberg J, Shanker V, et al. Penetrance and expression of dystonia genes. Adv Neurol. 2004;94:121-125.
19. Risch N, de Leon D, Ozelius L, et al. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet. 1995;9:152-159.
20. Ozelius L, Kramer PL, Moskowitz CB, et al. Human gene for torsion dystonia located on chromosome 9q32-q34. Neuron. 1989;2:1427-1434.
21. Kramer PL, de Leon D, Ozelius L, et al. Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32-34. Ann Neurol. 1990;27:114-120.
22. Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet. 1997;17:40-48.
23. Augood SJ, Martin DM, Ozelius LJ, et al. Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. Ann Neurol. 1999;46:761-769.
24. Augood SJ, Penney JB Jr, Friberg IK, et al. Expression of the early-onset torsion dystonia gene (DYT1) in human brain. Ann Neurol. 1998;43:669-673.
25. Shashidharan P, Good PF, Hsu A, et al. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res. 2000;877:379-381.
26. Furukawa Y, Hornykiewicz O, Fahn S, et al. Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation. Neurology. 2000;54:1193-1195.
27. Augood SJ, Hollingsworth Z, Albers DS, et al. Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study. Neurology. 2002;59:445-448.
28. Gasser T, Bressman S, Durr A, et al. Molecular diagnosis of inherited movement disorders: movement disorders society task force on molecular diagnosis. Mov Disord. 2002;18:3-18.
29. Bressman SB, Sabatti C, Raymond D, et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology. 2000;54:1746-1752.
30. Bressman SB, Raymond D, Wendt K, et al. Diagnostic criteria for dystonia in DYT1 families. Neurology. 2002;59:1780-1782.
31. Almasy L, Bressman SB, Raymond D, et al. Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol. 1997;42:670-673.
32. Valente EM, Bentivoglio AR, Cassetta E, et al. DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13-36.32 in an Italian family with cranial-cervical or upper limb onset. Ann Neurol. 2001;49:362-366.
33. Ozelius LJ. Update on the genetics of primary torsion dystonia loci DYT6, DYT7, and DYT13 and the dystonia-plus locus DYT12. Adv Neurol. 2004;94:109-112.
34. Leube B, Rudnicki D, Ratzlaff T, et al. Idiopathic torsion dystonia: assignment of a gene to chromosome 18p in a German family with adult onset, autosomal dominant inheritance and purely focal distribution. Hum Mol Genet. 1996;5:1673-1677.
35. Leube B, Hendgen T, Kessler KR, et al. Sporadic focal dystonia in northwest Germany: molecular basis on chromosome 18p. Ann Neurol. 1997;42:111-114.
36. Leube B, Hendgen T, Kessler KR, et al. Evidence for DYT7 being a common cause of cervical dystonia (torticollis) in central Europe. Am J Med Genet. 1997;74:529-532.
37. Klein C, Page CE, LeWitt P, et al. Genetic analysis of three patients with an 18p- syndrome and dystonia. Neurology. 1999;52:649-651.
38. Segawa M, Ohmi K, Itoh S, et al. Childhood basal ganglia disease with remarkable response to L-dopa: hereditary basal ganglia disease with marked diurnal fluctuation (in Japanese). Shinryo (Tokyo). 1971;24: 667-672.
39. Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet. 1994;8:236-242.
40. Nygaard TG, Wilhelmsen KC, Risch NJ, et al. Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q. Nat Genet. 1993;5:386-391.
41. Ichinose H, Suzuki T, Inagaki H, et al. Molecular genetics of dopa-responsive dystonia. Biol Chem. 1999;380:1355-1364.
42. Ludecke B, Dworniczak B, Bartholome K. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome. Hum Genet. 1995;95:123-125.
43. Grotzsch H, Pizzolato GP, Ghika J, et al. Neuropathology of a case of dopa-responsive dystonia associated with a new genetic locus, DYT14. Neurology. 2002;58:1839-1842.
44. Paviour DC, Surtees RAH, Lees AJ. Diagnostic considerations in juvenile parkinsonism. Mov Disord. 2004;19:123-135.
45. LeWitt PA, Miller LP, Levine RA, et al. Tetrahydrobiopterin in dystonia: identification of abnormal metabolism and therapeutic trials. Neurology. 1986;36:760-764.
46. Fink JK, Barton N, Cohen W, et al. Dystonia with marked diurnal variation associated with biopterin deficiency. Neurology. 1988;38:707-711.
47. Bandmann O, Nygaard TG, Surtees R, et al. Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. Hum Mol Genet. 1996;5:403-406.
48. Nygaard TG, Waran SP, Levine RA, et al. Dopa-responsive dystonia simulating cerebral palsy. Pediatr Neurol. 1994;11:236-240.
49. Patel K, Roskrow T, Davis JS, et al. Dopa responsive dystonia. Arch Dis Child. 1995;73:256-257.
50. Nygaard TG. Dopa-responsive dystonia: delineation of the clinical syndrome and clues to pathogenesis. Adv Neurol. 1993;60:577-585.
51. Tassin J, Durr A, Bonnet AM, et al. Levodopa-responsive dystonia: GTP cyclohydrolase I or parkin mutations? Brain. 2000;123:1112-1121.
52. Nygaard TG, Marsden CD, Duvoisin RC. Dopa-responsive dystonia. Adv Neurol. 1988;50:377-384.
53. Steinberger D, Weber Y, Korinthenberg R, et al. High penetrance and pronounced variation in expressivity of GCH1 mutations in five families with dopa-responsive dystonia. Ann Neurol. 1998;43:634-639.
54. Segawa M, Nomura Y, Nishiyama N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol. 2003;54(suppl 6):S32-S45.
55. Nygaard TG, Takahashi H, Heiman G, et al. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia. Ann Neurol. 1992;32:603-608.
56. Snow BJ, Nygaard TG, Takahashi H, et al. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann Neurol. 1993;34:733-738.
57. O'Sullivan JD, Costa DC, Gacinovic S, et al. SPECT imaging of the dopamine transporter in juvenile-onset dystonia. Neurology. 2001;56:266-267.
58. de Rijk-Van Andel JF, Gabreels FJ, Geurtz B, et al. L-dopa-responsive infantile hypokinetic rigid parkinsonism due to tyrosine hydroxylase deficiency. Neurology. 2000;55:1926-1928.
59. Nygaard TG, Raymond D, Chen C, et al. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol. 1999;46:794-798.
60. Vidailhet M, Tassin J, Durif F, et al. A major locus for several phenotypes of myoclonus-dystonia on chromosome 7q. Neurology. 2001;56:1213-1216.
61. Zimprich A, Grabowski M, Asmus F, et al. Mutations in the gene encoding e-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet. 2001;29:66-69.
62. Doheny DO, Brin MF, Morrison CE, et al. Phenotypic features of myoclonus-dystonia in three kindreds. Neurology. 2002;59:1187-1196.
63. Schule B, Kock N, Svetel M, et al. Genetic heterogeneity in ten families with myoclonus-dystonia. J Neurol Neurosurg Psychiatry. 2004;75:1181-1185.
64. Valente EM, Misbahuddin A, Brancati F, et al. Analysis of the epsilon-sarcoglycan gene in familial and sporadic myoclonus-dystonia: evidence for genetic heterogeneity. Mov Disord. 2003;18:1047-1051.
65. Grimes DA, Bulman D, George-Hyslop PS, et al. Inherited myoclonus-dystonia: evidence supporting genetic heterogeneity. Mov Disord. 2001;16:106-110.
66. Klein C, Brin MF, Kramer P, et al. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci U S A. 1999;96:5173-5176.
67. Asmus F, Zimprich A, Tezenas Du Montcel S, et al. Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol. 2002;52:489-492.
68. Grimes DA, Han F, Lang AE, et al. A novel locus for inherited myoclonus dystonia on 18p11. Neurology. 2002;59:1183-1186.
69. Furukawa Y, Rajput AH. Inherited myoclonus-dystonia: how many causative genes and clinical phenotypes? Neurology. 2002;59:1130-1131.
70. Goldman JG, Comella CL. Treatment of dystonia. Clin Neuropharmacol. 2003;26:102-108.
71. Jankovic J. Dystonia: medical therapy and botulinum toxin. Adv Neurol. 2004;94:275-286.
72. Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord. 1988;3:46-60.
73. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology. 1986;36:160-164.
74. Jabbari B, Scherokman B, Gunderson CH, et al. Treatment of movement disorders with trihexyphenidyl. Mov Disord. 1989;4:202-212.
75. Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol. 2004;11:361-370.
76. Fahn S. High dosage anticholinergic therapy in dystonia. Neurology. 1983;33:1255-1261.
77. Marsden CD, Marion MH, Quinn N. The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry. 1984;47:1166-1173.
78. Lang AE. High dose anticholinergic therapy in adult dystonia. Can J Neurol Sci. 1986;13:42-46.
79. Nutt JG, Hammerstad JP, deGarmo P, et al. Cranial dystonia: double-blind crossover study of anticholinergics. Neurology. 1984;34:215-217.
80. Taylor AE, Lang AE, Saint-Cyr JA, et al. Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies. Clin Neuropharmacol. 1991;14:62-77.
81. Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol. 1992;15:276-288.
82. Bressman SB. Dystonia update. Clin Neuropharmacol. 2000;23:239-251.
83. Bressman SB, Greene PE. Dystonia: current treatment options. Neurol. 2000;2:275-285.
84. Greene P, Shale H, Fahn S. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol. 1988;50:547-556.
85. Zuddas A, Cianchetti C. Efficacy of risperidone in idiopathic segmental dystonia. Lancet. 1996;347:127-128.
86. Karp BI, Goldstein SR, Chen R, et al. An open trial of clozapine for dystonia. Mov Disord. 1999;14:652-657.
87. Muller J, Wenning GK, Wissel J, et al. Riluzole therapy in cervical dystonia. Mov Disord. 2002;17:198-200.
88. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48:358-362.
89. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982;11:41-47.
90. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988;38:391-394.
91. Paleacu D, Giladi N, Moore O, et al. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol. 2004;27:230-233.
92. Narayan RK, Loubser PG, Jankovic J, et al. Intrathecal baclofen for intractable axial dystonia. Neurology. 1991;41:1141-1142.
93. Rawicki B. Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: long-term follow-up review of 18 patients. J Neurosurg. 1999;91:733-736.
94. Hou JG, Ondo W, Jankovic J. Intrathecal baclofen for dystonia. Mov Disord. 2001;16:1201-1202.
95. van Hilten JJ, Hoff JI, Thang MC, et al. Clinimetric issues of screening for responsiveness to intrathecal baclofen in dystonia. J Neural Transm. 1999;106:931-941.
96. van Hilten BJ, van de Beek WJ, Hoff JI, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med. 2000;343:625-630.
97. Albright AL, Barry MJ, Shafton DH, et al. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol. 2001;43:652-657.
98. Walker RH, Danisi FO, Swope DM, et al. Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov Disord. 2000;15:1242-1247.
99. Butler C, Campbell S. AACPDM Treatment Outcomes Committee Review Panel: evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. Dev Med Child Neurol. 2000;42:634-645.
100. Manji H, Howard RS, Miller DH, et al. Status dystonicus: the syndrome and its management. Brain. 1998;121(pt 2):243-252.
101. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981;33:155-188.
102. Rossetto O, Seveso M, Caccin P, et al. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon. 2001;39:27-41.
103. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6:S146-168.
104. Eleopra R, Tugnoli V, Quatrale R, et al. Different types of botulinum toxin in humans. Mov Disord. 2004;19(suppl 8):S53-59.
105. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord. 2004;19(suppl 8):S129-136.
106. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53:633-639.
107. Comella CL, Pullman SL. Botulinum toxins in neurological disease. Muscle Nerve. 2004;29:628-644.
108. Cordivari C, Misra VP, Catania S, et al. New therapeutic indications for botulinum toxins. Mov Disord. 2004;19(suppl 8):S157-161.
109. Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J Neurol Sci. 2005;235:1-9.
110. Reports of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Training guidelines for the use of botulinum toxin for the treatment of neurological disorders. Neurology. 1994;44:2401-2403.
111. Ondo WG, Desaloms JM, Jankovic J, et al. Pallidotomy for generalized dystonia. Mov Disord. 1998;13:693-698.
112. Tasker RR. Surgical treatment of the dystonias. In: Gildenberg PL, Tasker RR, eds. Textbook of Stereotactic and Functional Neurosurgery. New York: McGraw-Hill; 1998:1015-1032.
113. Vitek JL, Chockkan V, Zhang JY, et al. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol. 1999;46:22-35.
114. Lenz FA, Suarez JI, Metman LV, et al. Pallidal activity during dystonia: somatosensory reorganisation and changes with severity. J Neurol Neurosurg Psychiatry. 1998;65:767-770.
115. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13:281-285.
116. Lozano AM, Kumar R, Gross RE, et al. Globus pallidus internus pallidotomy for generalized dystonia. Mov Disord. 1997;12:865-870.
117. Krauss JK, Pohle T, Weber S, et al. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia. Lancet. 1999;354:837-838.
118. Kumar R, Dagher A, Hutchison WD, et al. Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. Neurology. 1999;53:871-874.
119. Tronnier VM, Fogel W. Pallidal stimulation for generalized dystonia: report of three cases. J Neurosurg. 2000;92:453-456.
120. Vercueil L, Pollak P, Fraix V, et al. Deep brain stimulation in the treatment of severe dystonia. J Neurol. 2001;248:695-700.
121. Merello M, Cerquetti D, Cammarota A, et al. Neuronal globus pallidus activity in patients with generalised dystonia. Mov Disord. 2004;19:548-554.
122. Bereznai B, Steude U, Seelos K, et al. Chronic high-frequency globus pallidus internus stimulation in different types of dystonia: a clinical, video, and MRI report of six patients presenting with segmental, cervical, and generalized dystonia. Mov Disord. 2002;17:138-144.
123. Krauss JK, Loher TJ, Pohle T, et al. Pallidal deep brain stimulation in patients with cervical dystonia and severe cervical dyskinesias with cervical myelopathy. J Neurol Neurosurg Psychiatry. 2002;72:249-256.
124. Parkin S, Aziz T, Gregory R, et al. Bilateral internal globus pallidus stimulation for the treatment of spasmodic torticollis. Mov Disord. 2001;16:489-493.
125. Krauss JK, Yianni J, Loher TJ, et al. Deep brain stimulation for dystonia. J Clin Neurophysiol. 2004;21:18-30.
126. Yianni J, Bain PG, Gregory RP, et al. Post-operative progress of dystonia patients following globus pallidus internus deep brain stimulation. Eur J Neurol. 2003;10:239-247.
127. Cif L, El Fertit H, Vayssiere N, et al. Treatment of dystonic syndromes by chronic electrical stimulation of the internal globus pallidus. J Neurosurg Sci. 2003;47:52-55.
128. Coubes P, Roubertie A, Vayssiere N, et al. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus. Lancet. 2000;355:2220-2221.
129. Yianni J, Bain P, Giladi N, et al. Globus pallidus internus deep brain stimulation for dystonic conditions: a prospective audit. Mov Disord. 2003;18:436-442.
130. Eltahawy HA, Saint-Cyr J, Giladi N, et al. Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. Neurosurgery. 2004;54:613-619.
131. Bhidayasiri R., Pulst SM. Dystonia (DYT) genetic loci. Eur J Paediatr Neurol. 2005;Jul 28 (Epub ahead of print).